MiNK Therapeutics to Host Engaging Virtual Shareholders Meeting

Author: Addison Perry Updated: 06-10-2025 01:45 PM

MiNK Therapeutics to Hold Annual Shareholders Meeting

MiNK Therapeutics, Inc. (NASDAQ: INKT), a pioneering biopharmaceutical company, has scheduled an exciting virtual Annual Shareholders Meeting. This event will take place at 9:30 a.m. ET and is designed to provide transparency and engagement for shareholders. Interested attendees are encouraged to register starting from 9:15 a.m. ET to ensure their participation.

How to Join the Meeting

To join this significant meeting, shareholders can visit www.virtualshareholdermeeting.com/INKT2025 and enter the unique 16-digit control number provided in their proxy materials. Guests wishing to join without voting rights can also participate in a listen-only mode, making it accessible for a wider audience.

Event Details

Webcast Information:

Date: Wednesday

Time: 9:30 a.m. ET

For those who cannot attend live, a replay of the meeting will be accessible from MiNK Therapeutics’ official website at https://investor.minktherapeutics.com/events-and-presentations and the Annual Shareholders Meeting link mentioned above.

About MiNK Therapeutics

MiNK Therapeutics is at the forefront of biopharmaceutical innovation, focusing on the development of allogeneic invariant natural killer T (iNKT) cell therapies. The company utilizes cutting-edge immune technologies to address challenging health issues ranging from cancer to immune-mediated diseases and pulmonary conditions. Their leading therapy, AGENT-797, represents an off-the-shelf solution for conditions like graft-versus-host disease (GvHD) and critical pulmonary immune collapse. MiNK Therapeutics is advancing a promising pipeline that emphasizes T cell receptor (TCR)-based therapies and tools for discovering neoantigens, aiming to enhance tumor and tissue-specific immune responses.

Innovative Approaches and Commitment

By leveraging a scalable manufacturing process, MiNK aims to make its advanced therapies accessible and durable across various medical indications. They are dedicated to bridging innate and adaptive immunity through next-generation immune reconstitution therapies.

Investor and Media Contacts

Investor Relations:
For investor-related inquiries, please contact:
917-362-1370
investor@minktherapeutics.com

Media Relations:
For media inquiries, reach out to:
781-674-4428
communications@minktherapeutics.com

Frequently Asked Questions

What is the date of the Annual Shareholders Meeting?

The Annual Shareholders Meeting is scheduled for June 18, 2025.

How can shareholders attend the meeting?

Shareholders can register online and enter their control number to attend, while guests can join in listen-only mode.

What technologies does MiNK Therapeutics focus on?

MiNK Therapeutics specializes in allogeneic iNKT cell therapies and immune technologies aimed at treating serious conditions like cancer and immune diseases.

What is AGENT-797?

AGENT-797 is MiNK's leading off-the-shelf iNKT cell therapy, currently being developed for various indications including GvHD and solid tumors.

Who can attend the Annual Shareholders Meeting?

Both shareholders and non-shareholders (as guests) can attend the meeting. Guests will have listen-only access.

About The Author

Hello, I'm 30-year-old financial writer and expert Addison Perry, and I love to simplify the intricacies of the financial industry. I've committed myself over the years to deciphering the subtleties of investing techniques and economic trends and converting them into doable guidance that anybody can use. My goal with writings and books is to make money interesting and approachable so that readers may take charge of their financial futures.

My enthusiasm to empowerment and education has propelled me through my career in finance. I write because I think that everyone should be able to make educated financial decisions, and I try to provide that. Regardless of experience level with investing, my work is intended to provide insightful analysis and practical advice to enable you to thrive in the always changing financial environment. I appreciate you traveling with me toward success and financial literacy.

Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.